Share Price and Basic Stock Data
Last Updated: December 31, 2025, 6:40 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Albert David Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹421 Cr and a share price of ₹737. The company reported total sales of ₹341 Cr for the fiscal year ending March 2023, which represented a growth from ₹313 Cr in the previous fiscal year. However, sales are forecasted to decline slightly to ₹345 Cr in March 2025, reflecting fluctuations in revenue generation. Quarterly sales data shows some volatility, with the highest quarterly sales recorded at ₹93.20 Cr in June 2022 and the lowest at ₹74.57 Cr in December 2022. The latest available quarterly revenue for June 2023 stood at ₹91.95 Cr. This revenue performance indicates the company’s ability to rebound after a challenging period, though it remains sensitive to market conditions and operational efficiency.
Profitability and Efficiency Metrics
Profitability metrics for Albert David Ltd reveal significant challenges, particularly in operating margins. The company’s operating profit margin (OPM) was negative at -15.11% as of March 2025, a stark decline from 13% in March 2022. This decline can be linked to rising expenses, which increased to ₹342 Cr in March 2025 from ₹272 Cr in March 2022. Net profit for the same fiscal year was reported at ₹17 Cr, down from ₹36 Cr in the previous year. The return on equity (ROE) stood at 4.39%, indicating low profitability relative to shareholder equity. Additionally, the interest coverage ratio (ICR) at 79.45x suggests that the company can comfortably meet its interest obligations, but overall profitability remains a concern given the declining profit margins.
Balance Sheet Strength and Financial Ratios
Albert David Ltd’s balance sheet reflects a conservative borrowing strategy, with total borrowings recorded at ₹41 Cr against total reserves of ₹388 Cr, resulting in a debt-to-equity ratio of 0.02. This low leverage indicates a strong financial position, allowing the company to maintain stability even in challenging market conditions. The current ratio stands at 3.40, suggesting robust liquidity, which is significantly above the typical industry benchmark of 1.5. However, the company’s return on capital employed (ROCE) is relatively low at 6.45%, indicating inefficiencies in utilizing capital for generating profits. Additionally, the price-to-book value (P/BV) ratio of 1.18x suggests that the stock is trading at a slight premium to its book value, which may reflect investor confidence despite the declining profitability metrics.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Albert David Ltd indicates a strong promoter presence, with promoters holding 62.23% of the total shares as of March 2025. This high level of promoter ownership typically signals confidence in the company’s long-term prospects. Foreign institutional investors (FIIs) account for only 0.60%, while domestic institutional investors (DIIs) hold 1.65%, suggesting a limited institutional interest. The public float stands at 35.50%, with the total number of shareholders recorded at 14,666. The gradual increase in public shareholding and the number of shareholders from 10,010 in December 2022 to 14,666 in March 2025 indicates growing retail investor interest, albeit the overall institutional engagement remains low, which may impact liquidity and market sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Albert David Ltd faces a mixed outlook. On the one hand, the company’s strong balance sheet and low debt levels provide a foundation for potential recovery and growth. However, the significant decline in profitability metrics, particularly the negative OPM and low ROCE, poses substantial risks. The pharmaceutical sector is competitive, and the company’s ability to innovate and manage operational costs will be critical for future growth. Additionally, fluctuations in sales and net profit could lead to increased volatility in investor sentiment. In light of these factors, stakeholders should closely monitor the company’s operational performance and market conditions, as the ability to reverse the current downward trend in profitability will be crucial for restoring investor confidence and enhancing overall financial health.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 231/84.3 | 28.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 442 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.4 Cr. | 35.8 | 36.4/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,197.40 Cr | 1,153.64 | 53.52 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 93.20 | 92.38 | 74.57 | 81.42 | 91.95 | 93.18 | 88.28 | 89.06 | 89.36 | 98.44 | 83.08 | 74.89 | 70.57 |
| Expenses | 80.99 | 78.13 | 66.28 | 71.83 | 78.96 | 77.21 | 79.92 | 79.49 | 88.48 | 92.22 | 82.40 | 79.64 | 81.23 |
| Operating Profit | 12.21 | 14.25 | 8.29 | 9.59 | 12.99 | 15.97 | 8.36 | 9.57 | 0.88 | 6.22 | 0.68 | -4.75 | -10.66 |
| OPM % | 13.10% | 15.43% | 11.12% | 11.78% | 14.13% | 17.14% | 9.47% | 10.75% | 0.98% | 6.32% | 0.82% | -6.34% | -15.11% |
| Other Income | -5.60 | 13.53 | 7.46 | 0.01 | 18.13 | 12.10 | 16.88 | 10.44 | 23.06 | 20.64 | -9.01 | -5.11 | 22.04 |
| Interest | 0.11 | 0.13 | 0.11 | 0.11 | 0.08 | 0.06 | 0.12 | 0.07 | 0.09 | 0.06 | 0.13 | 0.13 | 0.55 |
| Depreciation | 2.12 | 2.07 | 2.06 | 2.30 | 1.85 | 1.46 | 1.68 | 1.83 | 1.79 | 1.67 | 1.70 | 1.82 | 2.39 |
| Profit before tax | 4.38 | 25.58 | 13.58 | 7.19 | 29.19 | 26.55 | 23.44 | 18.11 | 22.06 | 25.13 | -10.16 | -11.81 | 8.44 |
| Tax % | 59.82% | 21.31% | 22.39% | 48.12% | 19.53% | 23.54% | 20.14% | 28.77% | 14.60% | 28.09% | -7.68% | -12.53% | 5.92% |
| Net Profit | 1.76 | 20.14 | 10.55 | 3.73 | 23.49 | 20.30 | 18.72 | 12.91 | 18.84 | 18.07 | -9.39 | -10.33 | 7.94 |
| EPS in Rs | 3.08 | 35.29 | 18.49 | 6.54 | 41.16 | 35.57 | 32.80 | 22.62 | 33.01 | 31.66 | -16.45 | -18.10 | 13.91 |
Last Updated: August 20, 2025, 2:05 pm
Below is a detailed analysis of the quarterly data for Albert David Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 70.57 Cr.. The value appears to be declining and may need further review. It has decreased from 74.89 Cr. (Mar 2025) to 70.57 Cr., marking a decrease of 4.32 Cr..
- For Expenses, as of Jun 2025, the value is 81.23 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.64 Cr. (Mar 2025) to 81.23 Cr., marking an increase of 1.59 Cr..
- For Operating Profit, as of Jun 2025, the value is -10.66 Cr.. The value appears to be declining and may need further review. It has decreased from -4.75 Cr. (Mar 2025) to -10.66 Cr., marking a decrease of 5.91 Cr..
- For OPM %, as of Jun 2025, the value is -15.11%. The value appears to be declining and may need further review. It has decreased from -6.34% (Mar 2025) to -15.11%, marking a decrease of 8.77%.
- For Other Income, as of Jun 2025, the value is 22.04 Cr.. The value appears strong and on an upward trend. It has increased from -5.11 Cr. (Mar 2025) to 22.04 Cr., marking an increase of 27.15 Cr..
- For Interest, as of Jun 2025, the value is 0.55 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.13 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.42 Cr..
- For Depreciation, as of Jun 2025, the value is 2.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.82 Cr. (Mar 2025) to 2.39 Cr., marking an increase of 0.57 Cr..
- For Profit before tax, as of Jun 2025, the value is 8.44 Cr.. The value appears strong and on an upward trend. It has increased from -11.81 Cr. (Mar 2025) to 8.44 Cr., marking an increase of 20.25 Cr..
- For Tax %, as of Jun 2025, the value is 5.92%. The value appears to be increasing, which may not be favorable. It has increased from -12.53% (Mar 2025) to 5.92%, marking an increase of 18.45%.
- For Net Profit, as of Jun 2025, the value is 7.94 Cr.. The value appears strong and on an upward trend. It has increased from -10.33 Cr. (Mar 2025) to 7.94 Cr., marking an increase of 18.27 Cr..
- For EPS in Rs, as of Jun 2025, the value is 13.91. The value appears strong and on an upward trend. It has increased from -18.10 (Mar 2025) to 13.91, marking an increase of 32.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 287 | 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 362 | 345 | 316 |
| Expenses | 254 | 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 315 | 342 | 328 |
| Operating Profit | 33 | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 | 3 | -12 |
| OPM % | 11% | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% | 1% | -4% |
| Other Income | 1 | 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 58 | 30 | 6 |
| Interest | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
| Depreciation | 11 | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 | 8 |
| Profit before tax | 18 | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 97 | 25 | -16 |
| Tax % | 32% | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | 22% | 32% | |
| Net Profit | 13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 17 | -15 |
| EPS in Rs | 22.02 | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 132.15 | 30.14 | -26.42 |
| Dividend Payout % | 23% | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 7.69% | 242.86% | -66.67% | -37.50% | 170.00% | -29.63% | 15.79% | 59.09% | 2.86% | 108.33% | -77.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 235.16% | -309.52% | 29.17% | 207.50% | -199.63% | 45.42% | 43.30% | -56.23% | 105.48% | -185.67% |
Albert David Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 3% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -2% |
| 3 Years: | -20% |
| TTM: | -91% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 13% |
| 3 Years: | 10% |
| 1 Year: | -50% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| Last Year: | 4% |
Last Updated: September 4, 2025, 10:40 pm
Balance Sheet
Last Updated: December 10, 2025, 2:20 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 85 | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 | 387 | 388 |
| Borrowings | 42 | 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 3 | 12 | 41 |
| Other Liabilities | 66 | 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 112 | 107 | 98 |
| Total Liabilities | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 | 533 |
| Fixed Assets | 67 | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 99 | 95 |
| CWIP | 3 | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 2 | 5 |
| Investments | 16 | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 260 | 277 |
| Other Assets | 111 | 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 135 | 151 | 156 |
| Total Assets | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 | 533 |
Below is a detailed analysis of the balance sheet data for Albert David Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Reserves, as of Sep 2025, the value is 388.00 Cr.. The value appears strong and on an upward trend. It has increased from 387.00 Cr. (Mar 2025) to 388.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Sep 2025, the value is 41.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 29.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 98.00 Cr.. The value appears to be improving (decreasing). It has decreased from 107.00 Cr. (Mar 2025) to 98.00 Cr., marking a decrease of 9.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 533.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 511.00 Cr. (Mar 2025) to 533.00 Cr., marking an increase of 22.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 95.00 Cr.. The value appears to be declining and may need further review. It has decreased from 99.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
- For Investments, as of Sep 2025, the value is 277.00 Cr.. The value appears strong and on an upward trend. It has increased from 260.00 Cr. (Mar 2025) to 277.00 Cr., marking an increase of 17.00 Cr..
- For Other Assets, as of Sep 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 151.00 Cr. (Mar 2025) to 156.00 Cr., marking an increase of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 533.00 Cr.. The value appears strong and on an upward trend. It has increased from 511.00 Cr. (Mar 2025) to 533.00 Cr., marking an increase of 22.00 Cr..
Notably, the Reserves (388.00 Cr.) exceed the Borrowings (41.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -9.00 | 7.00 | 11.00 | -3.00 | -10.00 | 30.00 | 28.00 | 17.00 | 35.00 | 39.00 | 44.00 | -9.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 | 30 | 29 |
| Inventory Days | 191 | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 149 | 126 | 201 |
| Days Payable | 135 | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 | 98 | 118 |
| Cash Conversion Cycle | 111 | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 | 58 | 112 |
| Working Capital Days | 21 | 27 | 25 | 24 | 10 | 21 | 18 | -10 | -34 | 14 | -13 | 6 |
| ROCE % | 18% | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% | 28% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 30.14 | 132.15 | 63.39 | 61.78 | 38.80 |
| Diluted EPS (Rs.) | 30.14 | 132.15 | 63.39 | 61.78 | 38.80 |
| Cash EPS (Rs.) | 42.35 | 144.11 | 78.36 | 77.21 | 53.22 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 687.70 | 671.05 | 545.93 | 489.68 | 428.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 687.70 | 671.05 | 545.93 | 489.68 | 428.20 |
| Dividend / Share (Rs.) | 5.00 | 11.50 | 9.00 | 9.00 | 6.00 |
| Revenue From Operations / Share (Rs.) | 605.85 | 635.10 | 598.48 | 549.33 | 433.57 |
| PBDIT / Share (Rs.) | 57.13 | 182.98 | 104.67 | 99.23 | 63.65 |
| PBIT / Share (Rs.) | 44.92 | 171.02 | 89.69 | 83.81 | 49.23 |
| PBT / Share (Rs.) | 44.20 | 170.46 | 88.90 | 82.87 | 48.09 |
| Net Profit / Share (Rs.) | 30.14 | 132.15 | 63.38 | 61.78 | 38.80 |
| PBDIT Margin (%) | 9.43 | 28.81 | 17.49 | 18.06 | 14.68 |
| PBIT Margin (%) | 7.41 | 26.92 | 14.98 | 15.25 | 11.35 |
| PBT Margin (%) | 7.29 | 26.84 | 14.85 | 15.08 | 11.09 |
| Net Profit Margin (%) | 4.97 | 20.80 | 10.59 | 11.24 | 8.94 |
| Return on Networth / Equity (%) | 4.38 | 19.69 | 11.61 | 12.61 | 9.06 |
| Return on Capital Employeed (%) | 6.29 | 24.46 | 15.77 | 16.27 | 10.77 |
| Return On Assets (%) | 3.36 | 15.14 | 8.54 | 8.75 | 6.48 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 0.68 | 0.78 | 0.82 | 0.84 | 0.74 |
| Current Ratio (X) | 3.40 | 3.75 | 3.07 | 2.33 | 2.77 |
| Quick Ratio (X) | 2.79 | 3.31 | 2.55 | 1.97 | 2.33 |
| Inventory Turnover Ratio (X) | 6.43 | 1.36 | 1.41 | 1.37 | 0.93 |
| Dividend Payout Ratio (NP) (%) | 38.15 | 6.81 | 14.19 | 9.71 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 27.15 | 6.24 | 11.48 | 7.77 | 0.00 |
| Earning Retention Ratio (%) | 61.85 | 93.19 | 85.81 | 90.29 | 0.00 |
| Cash Earning Retention Ratio (%) | 72.85 | 93.76 | 88.52 | 92.23 | 0.00 |
| Interest Coverage Ratio (X) | 79.45 | 325.13 | 131.04 | 106.40 | 55.62 |
| Interest Coverage Ratio (Post Tax) (X) | 42.91 | 235.81 | 80.35 | 67.24 | 34.90 |
| Enterprise Value (Cr.) | 471.38 | 584.89 | 270.90 | 288.62 | 180.08 |
| EV / Net Operating Revenue (X) | 1.36 | 1.61 | 0.79 | 0.92 | 0.72 |
| EV / EBITDA (X) | 14.46 | 5.60 | 4.53 | 5.10 | 4.96 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 1.69 | 0.85 | 0.96 | 0.86 |
| Retention Ratios (%) | 61.84 | 93.18 | 85.80 | 90.28 | 0.00 |
| Price / BV (X) | 1.18 | 1.60 | 0.93 | 1.09 | 0.87 |
| Price / Net Operating Revenue (X) | 1.34 | 1.69 | 0.85 | 0.96 | 0.86 |
| EarningsYield | 0.03 | 0.12 | 0.12 | 0.11 | 0.10 |
After reviewing the key financial ratios for Albert David Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 30.14. This value is within the healthy range. It has decreased from 132.15 (Mar 24) to 30.14, marking a decrease of 102.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 30.14. This value is within the healthy range. It has decreased from 132.15 (Mar 24) to 30.14, marking a decrease of 102.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 42.35. This value is within the healthy range. It has decreased from 144.11 (Mar 24) to 42.35, marking a decrease of 101.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 687.70. It has increased from 671.05 (Mar 24) to 687.70, marking an increase of 16.65.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 687.70. It has increased from 671.05 (Mar 24) to 687.70, marking an increase of 16.65.
- For Dividend / Share (Rs.), as of Mar 25, the value is 5.00. This value exceeds the healthy maximum of 3. It has decreased from 11.50 (Mar 24) to 5.00, marking a decrease of 6.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 605.85. It has decreased from 635.10 (Mar 24) to 605.85, marking a decrease of 29.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 57.13. This value is within the healthy range. It has decreased from 182.98 (Mar 24) to 57.13, marking a decrease of 125.85.
- For PBIT / Share (Rs.), as of Mar 25, the value is 44.92. This value is within the healthy range. It has decreased from 171.02 (Mar 24) to 44.92, marking a decrease of 126.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.20. This value is within the healthy range. It has decreased from 170.46 (Mar 24) to 44.20, marking a decrease of 126.26.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 30.14. This value is within the healthy range. It has decreased from 132.15 (Mar 24) to 30.14, marking a decrease of 102.01.
- For PBDIT Margin (%), as of Mar 25, the value is 9.43. This value is below the healthy minimum of 10. It has decreased from 28.81 (Mar 24) to 9.43, marking a decrease of 19.38.
- For PBIT Margin (%), as of Mar 25, the value is 7.41. This value is below the healthy minimum of 10. It has decreased from 26.92 (Mar 24) to 7.41, marking a decrease of 19.51.
- For PBT Margin (%), as of Mar 25, the value is 7.29. This value is below the healthy minimum of 10. It has decreased from 26.84 (Mar 24) to 7.29, marking a decrease of 19.55.
- For Net Profit Margin (%), as of Mar 25, the value is 4.97. This value is below the healthy minimum of 5. It has decreased from 20.80 (Mar 24) to 4.97, marking a decrease of 15.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.38. This value is below the healthy minimum of 15. It has decreased from 19.69 (Mar 24) to 4.38, marking a decrease of 15.31.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.29. This value is below the healthy minimum of 10. It has decreased from 24.46 (Mar 24) to 6.29, marking a decrease of 18.17.
- For Return On Assets (%), as of Mar 25, the value is 3.36. This value is below the healthy minimum of 5. It has decreased from 15.14 (Mar 24) to 3.36, marking a decrease of 11.78.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.68. It has decreased from 0.78 (Mar 24) to 0.68, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 3.40. This value exceeds the healthy maximum of 3. It has decreased from 3.75 (Mar 24) to 3.40, marking a decrease of 0.35.
- For Quick Ratio (X), as of Mar 25, the value is 2.79. This value exceeds the healthy maximum of 2. It has decreased from 3.31 (Mar 24) to 2.79, marking a decrease of 0.52.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.43. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 6.43, marking an increase of 5.07.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 38.15. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 38.15, marking an increase of 31.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 27.15. This value is within the healthy range. It has increased from 6.24 (Mar 24) to 27.15, marking an increase of 20.91.
- For Earning Retention Ratio (%), as of Mar 25, the value is 61.85. This value is within the healthy range. It has decreased from 93.19 (Mar 24) to 61.85, marking a decrease of 31.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 72.85. This value exceeds the healthy maximum of 70. It has decreased from 93.76 (Mar 24) to 72.85, marking a decrease of 20.91.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 79.45. This value is within the healthy range. It has decreased from 325.13 (Mar 24) to 79.45, marking a decrease of 245.68.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 42.91. This value is within the healthy range. It has decreased from 235.81 (Mar 24) to 42.91, marking a decrease of 192.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 471.38. It has decreased from 584.89 (Mar 24) to 471.38, marking a decrease of 113.51.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.61 (Mar 24) to 1.36, marking a decrease of 0.25.
- For EV / EBITDA (X), as of Mar 25, the value is 14.46. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 14.46, marking an increase of 8.86.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 1.69 (Mar 24) to 1.34, marking a decrease of 0.35.
- For Retention Ratios (%), as of Mar 25, the value is 61.84. This value is within the healthy range. It has decreased from 93.18 (Mar 24) to 61.84, marking a decrease of 31.34.
- For Price / BV (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.18, marking a decrease of 0.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 1.69 (Mar 24) to 1.34, marking a decrease of 0.35.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.12 (Mar 24) to 0.03, marking a decrease of 0.09.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Albert David Ltd:
- Net Profit Margin: 4.97%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.38% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 42.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.79
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.52)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.97%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | D - Block, 3rd Floor, Gillander House, Kolkata West Bengal 700001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Kumar Kothari | Exe.Chairman & W T D |
| Mr. Umesh Manohar Kunte | Managing Director & CEO |
| Mrs. Prabhawati Devi Kothari | Non Executive Director |
| Mr. Anand Vardhan Kothari | Non Executive Director |
| Mr. Anurag Singhi | Ind. Non-Executive Director |
| Mr. Shourya Sengupta | Ind. Non-Executive Director |
| Dr. Monjori Mitra | Ind. Non-Executive Director |
| Mr. Naresh Pachisia | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Albert David Ltd?
Albert David Ltd's intrinsic value (as of 31 December 2025) is ₹365.96 which is 50.34% lower the current market price of ₹737.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹419 Cr. market cap, FY2025-2026 high/low of ₹1,412/730, reserves of ₹388 Cr, and liabilities of ₹533 Cr.
What is the Market Cap of Albert David Ltd?
The Market Cap of Albert David Ltd is 419 Cr..
What is the current Stock Price of Albert David Ltd as on 31 December 2025?
The current stock price of Albert David Ltd as on 31 December 2025 is ₹737.
What is the High / Low of Albert David Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Albert David Ltd stocks is ₹1,412/730.
What is the Stock P/E of Albert David Ltd?
The Stock P/E of Albert David Ltd is .
What is the Book Value of Albert David Ltd?
The Book Value of Albert David Ltd is 690.
What is the Dividend Yield of Albert David Ltd?
The Dividend Yield of Albert David Ltd is 0.68 %.
What is the ROCE of Albert David Ltd?
The ROCE of Albert David Ltd is 6.45 %.
What is the ROE of Albert David Ltd?
The ROE of Albert David Ltd is 4.39 %.
What is the Face Value of Albert David Ltd?
The Face Value of Albert David Ltd is 10.0.